Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Junshi Biosciences (1877 HK)
Watchlist
213
Analysis
Health Care
•
China
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Thematic (Sector/Industry)
•
13 Feb 2022 09:12
China Healthcare Weekly (Feb.11)- “14th Five-Year Plan” For Medical Beauty, Wuxi Biologics, Innovent
We analyzed the “14th Five-year Plan” for medical beauty, the impact of WuXi Bio after being included in "unverified list" and the prospects of...
Xinyao (Criss) Wang
Follow
265 Views
Share
bearish
•
Lepu Biopharma
•
10 Feb 2022 16:54
Lepu Biopharma (乐普生物科技) IPO: Sentiment Cooled Down
Downsized deal amid cooled sentiment for Chapter 18A, we think the valuation of Lepu Biopharm is not attractive for investors.
Ke Yan, CFA, FRM
Follow
287 Views
Share
bearish
•
Thematic (Sector/Industry)
•
10 Feb 2022 09:05
Would the Cheap Versions of Oral COVID-19 Antiviral Bring New Opportunities for Chinese Companies?
Some Chinese companies are allowed to make cheap versions of Merck’s molnupiravir based on the MPP agreement.We analyzed the impact and outlook,...
Xinyao (Criss) Wang
Follow
225 Views
Share
bullish
•
Thematic (Sector/Industry)
•
09 Feb 2022 09:01
Interpretation of The "14th Five-Year Plan" For the Development of China Pharmaceutical Industry
For the newly released "14th Five-year Plan" of China pharmaceutical industry, we analyzed key points and our interpretation. Once achieved, it...
Xinyao (Criss) Wang
Follow
373 Views
Share
bearish
•
Quantitative Analysis
•
16 Jan 2022 12:29
A/H Premium Weekly: Biggest A/H Premium Declines in a Year
The market average A/H premium registered the biggest declines in the past one year. We highlight top sectors by the decline of A/H premium, as...
Ke Yan, CFA, FRM
Follow
309 Views
Share
First
Previous
20
21
22
23
24
25
26
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x